arthritis advocacy news and regulatory letters

Advocacy News & Regulatory Letters

November 27, 2017

Arthritis Foundation Comments on The Proposed HHS Notice Benefits and Payment Parameters Rule for 2019

The Arthritis Foundation submitted comments to the Department of Health and Human Services (HHS) on the proposed Notice of Benefit and Payment Parameters for 2019. The proposal affects the insurance exchanges. Our comments focused on the need to maintain important patient protections under current law, such as preserving the essential health benefits. Read the letter.  The Foundation also joined 138 other patient groups by signing on to an I Am Essential Coalition letter to express similar concern about the proposals. Read the coalition letter here.

November 17, 2017

Arthritis Foundation Comments on New Direction for CMMI

The Arthritis Foundation submitted public comments to the Center for Medicare & Medicaid Innovation (CMMI). The CMMI supports the development and testing of innovative health care payment and delivery models, and is seeking to chart a new direction that would empower patients and health care consumers. The Foundation focused its comments on the importance of placing patients at the center of the CMMI’s work, and ensuring their perspectives are incorporated into new models of care. Read our comments.

November 14, 2017

Arthritis Foundation Concerned by Individual Mandate Repeal in Tax Reform Package

Congressional leaders are expected to move forward with a repeal of the individual mandate in their tax reform legislation. The individual mandate, established by the Affordable Care Act, requires individuals to have health insurance or face a tax penalty. The individual mandate helps to stabilize the health insurance marketplace by assuring all Americans have access to affordable, quality care. The Arthritis Foundation released the following statement expressing concern about the latest development and the impact such a move could have on the stability of the health insurance marketplace. Read our statement.

November 2, 2017

Arthritis Community Applauds CMS Decision to Reverse Biosimilars Policy

Together with the American College of Rheumatology, National Psoriasis Foundation, and American Autoimmune and Related Diseases Association, the Arthritis Foundation applauds the Centers for Medicare and Medicaid Services (CMS) for its reversal in policy for how it reimburses for biosimilars in Medicare Part B. Read our joint statement and find out what it means now that this policy is reversed. 

October 27, 2017

Arthritis Foundation Urges Patient-Centered Solutions as Cornerstone of Department of Health and Human Services Strategic Plan

On Friday, October 27, the Arthritis Foundation submitted comments to the Department of Health and Human Services in response to their Strategic Plan for Fiscal Years 2018-2022. In the letter, the Arthritis Foundation encourages HHS to continue working toward a goal of patient-centered health care solutions and modernizing the nation's health care system to protect Americans no matter where they may live across the country. Click here to read more.

October 26, 2017

Bipartisan Health Care Stabilization Act Would Benefit Patients and Families

On Thursday, the Congressional Budget Office (CBO) analyzed bipartisan legislation introduced by Senators Lamar Alexander (R-TN) and Patty Murray (D-WA), finding that the bill would result in savings to the federal government, no impact on insurance premiums for 2018, and no substantial change in the number of insured individuals across the country. The Arthritis Foundation is pleased with the CBO report and released a joint statement with seventeen other nonpartisan patient, provider, and consumer groups to urge Congress to take action on this legislation. Read the statement here.

October 19, 2017

Arthritis Foundation Praises Bipartisan Agreement to Provide Stability to Individual Insurance Markets

On Tuesday, October 17, Senators Lamar Alexander (R-TN) and Patty Murray (D-WA) announced a tentative bipartisan agreement to stabilize the individual health insurance markets. The legislation also preserves and supports key protections for individuals with preexisting conditions and is a positive first step to stabilize the individual insurance markets. The Arthritis Foundation joined 28 other patient and provider groups praising the return to bipartisanship. In its current form, the plan would maintain access to quality and affordable health care for all Americans. Read the statement here.

October 13, 2017

Answering Your Questions About the Latest Administration Actions on Health Care

On October 12, 2017, the Administration took two actions on health care that could affect coverage for people who have health insurance through the exchanges. President Trump signed an executive order that opens the door for the expansion of Association Health Plans, which aren’t subject to the same level of patient protections as required by the Affordable Care Act (ACA). Second, the Administration announced the discontinuation of cost-sharing reduction payments, which are payments to health insurers that help reduce out-of-pocket costs for low income people who purchase insurance on the health exchanges. Learn more about how these actions could impact patients here.

October 13, 2017

Arthritis Foundation Implores Congress to Fund Cost-Sharing Payments

On Friday, the Arthritis Foundation joined 11 other patient groups expressing disappointment that the Administration has decided to discontinue funding for cost-sharing reduction payments, which are made to insurers to help reduce out-of-pocket costs for low income people to purchase insurance on the health care exchanges. The letter urged Congress to take immediate bipartisan action to fund these payments. Click here to read further.

October 12, 2017

Arthritis Foundation & 17 Other Groups Express Concern About the President’s Executive Order on Health Insurance

On Thursday, the Arthritis Foundation, along with 17 other groups, expressed concern about how the Administration’s health care executive order would impact patient protections. The executive order opens the door to a weakening of important patient protections like essential health benefits, such as prescription drugs. The order also has the potential to price people with pre-existing conditions out of the individual insurance marketplace. Click here to read more.

September 26, 2017

Arthritis Foundation Pleased Graham-Cassidy Will Not Come Up for Vote; Urges Return to Bipartisanship

With limited support for the bill, Senate Majority Leader Mitch McConnell announced today the bill will not be called for vote. While we are pleased Graham-Cassidy will not move forward, we recognize that improvements must be made. We urge members of Congress to revisit the bipartisan process started earlier this month. Read our full statement

September 25, 2017

Arthritis Foundation: Concerned Graham-Cassidy Could Jeopardize Care for the Arthritis Community

The Arthritis Foundation continues to strongly urge Congress to consider bipartisan solutions to strengthen the health care system. We believe that patients are the ultimate stakeholders in health care, and the Graham-Cassidy bill would jeopardize care for far too many. Read our statement on the legislation.

September 18, 2017

Arthritis Foundation Joins 15 Patient and Provider Groups to Oppose Latest Bill to Repeal and Replace Affordable Care Act

On September 18, the Arthritis Foundation joined over a dozen patient and provider organizations to oppose the latest bill to repeal and replace the Affordable Care Act. The bill was introduced last week by Senators Lindsay Graham (R-SC) and Bill Cassidy (R-LA) and does not adequately protect people with pre-existing conditions and does not align with the Arthritis Foundation’s legislative patient principles. The Arthritis Foundation continues to strongly urge Congress to consider bipartisan solutions to strengthen the health care system, most recently in a letter sent to Congressional leadership last month. Read the statement on the legislation.

September 8, 2017

Arthritis Foundation Sends Comments to the California Department of Managed Health Care Regarding Standardized Formularies

The Arthritis Foundation submitted comments on the proposed rulemaking regarding standardized formularies in California, as a result of the passage of Senate Bill 1052. Formulary transparency and adequacy make it easier for those with serious conditions to choose a plan that will cover the prescription medications they need. We were supportive of Senate Bill 1052 when it went through the legislative process, including sending letters and organizing patients to testify during hearings. Read our comments.

August 29, 2017

Arthritis Foundation Comments on Medicare Physician Fee Schedule

The Arthritis Foundation submitted public comments to the Centers for Medicare & Medicaid Services (CMS) regarding the Medicare Physician Fee Schedule (MPFS) for calendar year 2018. The fee schedule is used by Medicare to reimburse physicians for services. The Foundation focused its comments on the current policy for reimbursing biosimilar drugs. Read the letter.

August 18, 2017

Arthritis Foundation Sends Comment to the Washington Insurance Commissioner Regarding Prior Authorization

On August 18, the Arthritis Foundation submitted comments to the Washington State Office of the Insurance Commissioner regarding their call for written comments on prior authorization gold card programs.

The Arthritis Foundation appreciates that the Washington Office of the Insurance Commissioner is considering this important issue and is soliciting public comments on optimizing prior authorization. A standardized process for prior authorization approvals through the use of a gold card program would greatly benefit all stakeholders in the health care system, and in particular the millions of patients across the state who rely on regular, timely access to treatment to manage their disease. Read the letter.

August 18

Food and Drug Administration Reauthorization Act Signed Into Law

President Trump signed the Food and Drug Administration Reauthorization Act into law, which reauthorizes critical user fee agreements allowing the Food and Drug Administration (FDA) to continue its mission of regulating drugs and devices. Every five years, Congress must pass legislation reauthorizing the fees that the FDA receives from drug and device companies. These fees help fund the FDA’s work to review and approve new medicines and devices. We are pleased that the act emphasizes the importance of including the patient's voice in drug development and decision-making. Our community of advocates look forward to continued opportunities to engage with the FDA.

The Arthritis Foundation was engaged with the FDA and lawmakers in reauthorizing the act for nearly two years. Our work included providing feedback on appropriate patient engagement as well as organizing a day in March for members of the Arthritis Foundation's Board of Directors to educate Congress on the importance of patient-centered strategies in the drug approval process. 

August 16

Arthritis Foundation Offers Policy Recommendations to Strengthen Affordable Care Act

On August 16, the Arthritis Foundation sent a letter to House and Senate leadership describing four policy recommendations that can help strengthen and improve the Affordable Care Act. The Foundation sent the letter after Congress indicated it was renewing efforts to find bipartisan solutions. Read the letter.

August 2

Arthritis Foundation Joins 12 Patient Advocacy Organizations to Urge Bipartisan Solutions for Health Reform

On August 2, 2017, the Arthritis Foundation joined 12 other patient advocacy organizations to urge Congress to work together in a bipartisan manner to improve and strengthen the nation’s health care system. The statement emphasizes the need for Congress to work across the aisle to identify policy solutions that help stabilize the insurance marketplace and address affordability of health care for patients. Read the letter.

July 31

Repeal Bill Fails in the Senate. What Happens Next?

Last Friday, the Senate’s effort to repeal the Affordable Care Act (ACA) failed by a vote of 49 to 51. While it is unclear what Senate leaders will do next, a bipartisan group of lawmakers unveiled a plan today with the short-term goal of stabilizing the insurance markets. The lawmakers also proposed a number of ideas they believe can be accepted by a majority of the Members of Congress as long-term fixes. The Arthritis Foundation, along with many other patient advocacy groups, has long called for bipartisan solutions to strengthen current laws and will be working in the coming months to ensure that the issues people with arthritis face remain at the forefront of Congressional discussions.

July 20

Response to Congressional Budget Office Cost Estimates on Proposed Repeal and Replace Health Care Legislation

Congressional Budget Office recently released cost estimates on various versions of recently proposed health care repeal and replace legislation. We believe Americans deserve a transparent health care system that allows for informed decisions but does not put people at risk of losing coverage. Read our full statement here.

July 18

ACA Repeal Statement

The Arthritis Foundation joined 14 other nonpartisan patient and provider groups representing millions of Americans in issuing a statement imploring lawmakers to sit down in a bipartisan fashion and draft a new health care bill that will strengthen and expand access to affordable and adequate health care coverage. Read the statement here.

June 27

Senate Health Bill Statement

The Arthritis Foundation expresses concern following today’s release of the Congressional Budget Office (CBO) score of the Better Care Reconciliation Act, which estimates 22 million Americans would lose coverage under the bill. Arthritis is a complex, chronic condition and people with arthritis depend on access to timely, regular care to control their disease. The threat of losing health care coverage would be harmful to patients and could result in severe health consequences, leading to greater health care costs over time.

While we understand the current health care system needs reform, we call on the Senate and all members of Congress to work with the patient community on solutions that truly work for patients. The Arthritis Foundation has set out patient principles that are critical to protecting the health care of people with arthritis. These principles include ensuring caps on annual out of pocket costs, maintaining the ban on lifetime cost limits, and preserving the essential health benefits. Under the Senate bill, patients are at risk of not only losing these critical protections but also of losing coverage altogether. 

Read, download and learn more information about the BCRA.

June 23

The Better Care Reconciliation Act: What You Need to Know

On Thursday, June 22, 2017, the Senate introduced its version of health reform legislation, the Better Care Reconciliation Act (BCRA). While BCRA is similar to the House’s American Health Care Act (AHCA), the Senate legislation contains some key differences. We are on the job, working hard to ensure that YOU have affordable access to the care you need. Learn how this bill might change your coverage, costs and access to medical care, and the actions we are taking. Read, download and share the PDF.

June 23

The Better Care Reconciliation Act: What You Need to Know

On Thursday, June 22, 2017, the Senate introduced its version of health reform legislation, the Better Care Reconciliation Act (BCRA). While BCRA is similar to the House’s American Health Care Act (AHCA), the Senate legislation contains some key differences. We are on the job, working hard to ensure that YOU have affordable access to the care you need. Learn how this bill might change your coverage, costs and access to medical care, and the actions we are taking. Read, download and share the PDF.

June 15

Arthritis Foundation Signs Letter to Express Concern Over Proposed Changes to Medicaid

The Arthritis Foundation along with nearly 130 other organizations, signed onto a letter to the Senate Finance Committee and Leadership to address grave concerns about potential changes to the fundamental structure and purpose of Medicaid.  The letter emphasizes that Medicaid is a critical lifeline for patients and consumers, that funding for Medicaid must be maintained, and that Medicaid expansion is essential to protecting some of the most vulnerable Americans. Read the letter here.

June 8

Arthritis Foundation Urges the Department of Health and Human Services to Protect Medicare Part B

The Arthritis Foundation, along with 268 other organizations, signed onto a letter to urge the Department of Health and Human Services to protect the Medicare Part B Program.  This program reimburses providers for medications that are administered by physicians to some of the most vulnerable patients enrolled in Medicare. The letter expresses concern over policy recommendations that would jeopardize access to care, force clinics to close, and could even diminish a provider’s ability to administer personalized care. You can read the letter here.

May 24 

The Arthritis Foundation Supports Legislation to Limit Step Therapy at the Federal Level

The Arthritis Foundation, along with nearly 30 other patient organizations, signed onto a letter in support of a piece of federal legislation, H.R. 2077, the Restoring the Patient’s Voice Act of 2017, that would limit the use of Step Therapy. The Arthritis Foundation has successfully engaged to enact legislation that limits step therapy in many states across the country and is excited to see a bill proposed at the federal level. This important piece of legislation will provide a clear and transparent process that will help ease the burden of step therapy protocols for patients in America. You can read the letter here!

May 23

President’s Fiscal Year 2018 Budget Request Jeopardizes Critical Public Health Programs

Today, the president released the administration's official budget request for fiscal year (FY) 2018, which would make deep cuts to health programs across health agencies and would have severe implications for Medicaid and other programs that deliver vital health care services to people with arthritis. While the Arthritis Foundation agrees that health care reform is necessary and our country needs to make important spending decisions, it should not be at the expense of people with arthritis.

May 8

The Arthritis Foundation Signs Coalition Letter to Congress in Support of Health Funding

The Arthritis Foundation joined nearly 800 organizations from the Coalition for Health Funding, the Committee for Education Funding, and the Campaign to Invest in America’s Workforce in calling for an increase in health funding appropriations for the Departments of Labor, Health and Human Services, and Education and Related Agencies (Labor-HHS). The activities that Labor-HHS oversees serve a broad range of communities and needs, but they all share a common, fundamental goal of strengthening this nation by improving Americans’ lives. Increasing this important appropriation would make possible the investment in important initiatives like the expansion of medical research at the National Institutes of Health (NIH)! You can read the full letter here.

May 8

The Arthritis Foundation Signs Coalition Letters in Support of Increased Transparency in Healthcare

The Arthritis Foundation joined six other patient and healthcare provider organizations in signing onto two letters that address transparency in the healthcare system. The letters are on behalf of the Alliance for Transparent and Affordable Prescriptions (ATAP), a coalition of provider and patient groups who have joined together over a shared concern with the practices of pharmacy benefit managers (PBM). In the first letter to Congressman Collins, the ATAP coalition offers support of the Prescription Drug Price Transparency Act, a bill that will address unpredictability and transparency in PBM dealings with pharmacies. In the second letter to Senator Wyden, the ATAP coalition supports the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act which addresses transparency with regard to rebates.

May 5

The American Health Care Act: What You Need to Know

Yesterday, the House of Representatives passed the American Health Care Act (AHCA). The bill changes several key features of the Affordable Care Act and has now moved to the Senate where it could get voted on, as is, or amended and sent back to the House for further consideration. We are concerned with how the AHCA might change health care coverage, costs and access, and have created The Health Care Bill: What You Need to Know, to help explain some of the more impactful implications of this bill. Read the document here

May 5

The Arthritis Foundation Signs Letter to Urge the Swift Reauthorization of the Food and Drug Administration (FDA) User Fee Agreements

The Arthritis Foundation joined over 100 healthcare and patient advocacy organizations to urge Congressional leadership to reauthorize the FDA’s user fee acts. The FDA largely relies on user fees authorized by Congress to operate. The chronic and rare disease and disability patient communities count on the FDA to ensure that innovative, safe, and effective treatments reach those in need. The letter highlights the need for the user fee reauthorization process to remain timely, bipartisan, uncontentious, and focused on the patients FDA serves every day. You can read the letter here.

April 28

Ann Palmer, President and CEO of the Arthritis Foundation, Addresses Congressional Leadership about Continued Concerns with the American Health Care Act

Ann Palmer addressed Congressional Leadership in a letter that expresses concern about the American Health Care Act (ACHA) and MacArthur Amendment. The letter outlines several policy recommendations that the Arthritis Foundation believes are critical to ensure that arthritis patients can continue to access and afford their health care. The Arthritis Foundation remains concerned that some provisions of the AHCA could create access barriers to the care of people with arthritis. Read the letter.

April 7

Arthritis Foundation Proclaims a Patient Advocacy Win Through Its Work with the Institute for Clinical and Economic Review (ICER)

On April 7, 2017, ICER released the final report finding drug prices high but citing inadequate evidence to distinguish clinical benefit between the rheumatoid arthritis (RA) treatments. The organization also provided recommendations to the health care industry to ensure continuity and increased access to care for patients with RA. The Arthritis Foundation helped influence ICER by sharing stories of people living with RA and their experiences with disease-modifying drugs in managing their disease. Read more about our involvement with ICER.

April 3, 2017

Arthritis Foundation Signs Letter to the Institute for Clinical and Economic Review (ICER)  on the Proposed Revisions to ICER’s Value Framework

The Arthritis Foundation joined 37 other patient and provider groups by signing a letter from the Partnership to Improve Patient Care (PIPC) to provide feedback on proposed revisions to ICER’s value framework. Though ICER has solicited comments from stakeholders on its value assessment framework, the Arthritis Foundation believes there are additional steps that ICER must take beyond its proposed revisions to ensure that its framework is truly patient centered. Read the letter here.

April 3, 2017

Arthritis Foundation Submits Comments to The Institute for Clinical and Economic Review (ICER) on the Public Engagement Process

The Institute for Clinical and Economic Review (ICER) recently published draft guides on patient participation and an open input guide for patients. Representatives from the Arthritis Foundation, including five patients, reviewed ICER’s materials and provided written commentary on the guides. Striving to ensure the patient voice is heard, we urged ICER to make the patient engagement process transparent and easy to navigate. Read the letter here.

April 3, 2017

Arthritis Foundation Signs Letter to the Medicare Payment Advisory Commission (MedPac) Urging Reconsideration of Harmful Changes to PartB

The Arthritis Foundation joined more than 180 patient and provider groups in signing a letter from the Part B Access for Seniors and Physicians (ASP) Coalition, urging MedPac to reconsider harmful proposed changes to PartB which provides seniors access to lifesaving medicines. Preserving access must be a priority! The Arthritis Foundation is committed to protecting patient's access to the treatments they need. Read the letter here.

March 21, 2017

Arthritis Foundation Supports Medicaid Expansion along with Nearly 30 Other Patient Advocacy Organizations in Sign on Letter to House Leadership

The Arthritis Foundation speaks out against proposals to phase our Medicaid expansion along with nearly 30 other patient advocacy organizations in sign-on letter to House Leadership. The letter emphasizes that Medicaid is critical for patients, that converting the federal financing of Medicaid to a per capita cap system would negatively impact patients, and that failing to expand Medicaid would result in millions of people losing coverage. Moving forward, the Arthritis Foundation hopes to continue dialogue with House Leadership that will help to arrive at solutions that provide all Americans with high-quality, affordable care. Read the letter here!

March 21, 2017

Ann Palmer, President and CEO of the Arthritis Foundation, Addresses Congressional Leadership to Raise Concerns about the American Health Care Act

Ann Palmer addressed Congressional Leadership in a letter that expresses concern about the American Health Care Act (ACHA). The letter outlines several of our patient principles that the Arthritis Foundation is encouraged to see included in the AHCA, along with concerns about other patient protections not considered in the bill. These provisions are critical to ensure that arthritis patients can continue to access and afford their health care. The Arthritis Foundation remains concerned that some provisions of the AHCA could create access barriers to the care people with arthritis. Read the letter here.

March 15, 2017

Arthritis Foundation Encourages Members of Congress to Increase Funding and Support for the Centers for Disease Control and Prevention (CDC) Arthritis Program

The Arthritis Foundation, along with seven other patient and provider groups, signed onto letters to the United States House of Representatives and Senate asking for both a strong topline appropriation for the CDC Division of Population Health, and an appropriation of $16 million to the CDC Arthritis Program in the FY18 Labor, HHS, and Education Appropriations bill. The letter calls on Members of Congress to increase in funding for the CDC Arthritis Program by $5 million to meet the growing demand and need for arthritis research in the United States.  An estimated 78 million Americans will have arthritis by 2040. It is the leading cause of disability in the US, and it contributes to over $156 billion a year in direct medical costs and lost productivity. Read the letter to the Senate and the letter to the House.

March 15, 2017

Arthritis Foundation Comments on Proposed Rule on Orthotics and Prosthetics from the Centers for Medicare and Medicaid Services

Centers for Medicare and Medicaid Services (CMS) proposed a rule that would add  requirements to  the credentials needed for qualified practitioners to furnish and fabricate prosthetics and custom-fabricated orthotics, and for qualified suppliers to fabricate prosthetics and custom-fabricated orthotics. The Arthritis Foundation has submitted public comments to CMS seeking further clarification on certain provisions of the rule. The Foundation cannot support any provisions that could disrupt patient care and diminish quality of life for arthritis patients. Read the letter here.

March 13, 2017

Arthritis Foundation Shares Official Statement on American Health Care Act (AHCA)

Arthritis is a complex, chronic condition and people with arthritis depend on access to timely, ongoing care to control their disease. For many, access to health care is the difference between being disabled and being a fully functioning member of society.

The Arthritis Foundation believes people with arthritis should not fear that they will be unable to afford or access health care, including physicians, medications and other treatments. As such, we are sharing the principles we urge Congress to consider as it works towards health reform replacement legislation.

March 9, 2017

Arthritis Foundation Signs Letter to Support Reduced Out of Pocket Costs for Patients in Health Care Reform

The Arthritis Foundation joined 35 patient and provider groups to sign onto a letter from the Coalition for Accessible Treatments to urge the leadership on Capitol Hill to ensure healthcare legislation related to the Affordable Care Act (ACA) reduces out-of-pocket costs for patients and their families. The Arthritis Foundation is committed to continuing to protect patients with arthritis conditions attain access to the treatments they need. Read the letter here.

March 7, 2017

The Arthritis Foundation Submits Testimony in Support of Increased Funding for the CDC Arthritis Program

The Arthritis Foundation submitted written testimony to the House Appropriations Committee asking for an increase in funding for the CDC Arthritis Program – the only federal program dedicated solely to arthritis – and for sufficient funding for the National Institutes of Health to build on its investment in arthritis research. Read the testimony here.

March 3, 2017

Arthritis Foundation Sends Letter to Department of Health and Human Services (HHS) on Important Insurance Market Protections

The Arthritis Foundation sent a letter to HHS Secretary Tom Price, MD on a proposal he put out intended to stabilize the Affordable Care Act (ACA) Health Exchange market. The proposal would make changes to open enrollment periods and annual guarantees of coverage, among other things. The Arthritis Foundation stressed the need for people with arthritis to have personalized resources to help them make the best health plan decisions, and to have continuous, affordable access to the care that best suits their needs. Read the letter here.

February 17, 2017

Arthritis Foundation Submits Comments to The Institute for Clinical and Economic Review (ICER) on their Draft Evidence Report for their Review of Rheumatoid Arthritis Drugs

The Institute for Clinical and Economic Review (ICER) recently published a draft evidence report on the review of rheumatoid arthritis (RA) drugs. The Arthritis Foundation has provided written and verbal commentary to ICER on this report to help to ensure that patient voices are heard by ICER. It is imperative that input from patients and providers is considered and included during the development of a review for life changing treatments like those used for rheumatoid arthritis. Read the letter here.

Visit our page to learn more about the written and verbal commentary we have provided to ICER.

February 13, 2017

Arthritis Foundation Signs Letter to the Trump Administration in Support of Patient Centered Health Care Reform

The Arthritis Foundation, along with 200 other patient and community organizations, signed onto an I Am Essential coalition letter to the newly confirmed Secretary of Health and Human Services, Tom Price. The letter advocates for patient centric health reform legislation and urges the Trump administration to maintain the many important protections patients have gained through the Affordable Care Act that ensure they can access the care and treatment their providers prescribe. In the letter, the coalition supports accessibility, affordability, quality, responsiveness, choices and transparency, and innovative patient-care. Read the letter here.

January 30, 2017

Arthritis Foundation Provides Written and Verbal Commentary to Institute for Clinical and Economic Review (ICER)

ICER is a Boston-based non-profit organization that evaluates the clinical effectiveness and the cost of medical tests, treatments and delivery system innovations. Currently, ICER is reviewing rheumatoid arthritis therapies and will develop a report assessing their clinical effectiveness and value. ICER has also developed a value assessment framework to assess the cost and value of medications that many stakeholders have called into question. The Arthritis Foundation has provided written and verbal commentary and input to ICER at all available points so far in this evaluation process for RA drugs.

Visit our page to learn more about the written and verbal commentary we have provided and to see the summary of the remaining timeline in ICER’s review process for RA drugs.

Older News by Year